- - oalib

OALib Journal期刊
ISSN: 2333-9721
费用：99美元

投递稿件

为什么选择我们？ >>

- 开源期刊

- 同行审议

- 快速出刊

- 终身存储

- 免费检索

- 免费推广

- 更多...

- 搜索引擎

-

ISSN Print: 2044-5385

ISSN Online:

主页: https://www.nature.com/bcj

分享:

CBFβ-MYH11 interferes with megakaryocyte differentiation via modulating a gene program that includes GATA2 and KLF1

Umbilical cord blood versus unrelated donor transplantation in adults with primary refractory or relapsed acute myeloid leukemia: a report from Eurocord, the Acute Leukemia Working Party and the Cord Blood Committee of the Cellular Therapy and Immunobiology Working Party of the EBMT

Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study

Two types of amyloidosis presenting in a single patient: a case series

Cereblon-binding proteins expression levels correlate with hyperdiploidy in newly diagnosed multiple myeloma patients

Natural history of multiple myeloma with de novo del(17p)

Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma

Polyclonal serum free light chain elevation is associated with increased risk of monoclonal gammopathies

The journey to CAR T cell therapy: the pediatric and young adult experience with relapsed or refractory B-ALL

Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapse

Phase I trial of isatuximab monotherapy in the treatment of refractory multiple myeloma

Management of cardiovascular risk in patients with multiple myeloma

Identification of lenalidomide resistance pathways in myeloma and targeted resensitization using cereblon replacement, inhibition of STAT3 or targeting of IRF4

Molecular signatures of multiple myeloma progression through single cell RNA-Seq

Late relapse in acute myeloid leukemia (AML): clonal evolution or therapy-related leukemia?

Treatment of patients with multiple myeloma progressing on frontline-therapy with lenalidomide

ABCB1 SNP predicts outcome in patients with acute myeloid leukemia treated with Gemtuzumab ozogamicin: a report from Children’s Oncology Group AAML0531 Trial

Molecular underpinnings of clinical disparity patterns in African American vs. Caucasian American multiple myeloma patients

Reverse signaling via PD-L1 supports malignant cell growth and survival in classical Hodgkin lymphoma

Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myeloma

High frequencies of circulating memory T cells specific for calreticulin exon 9 mutations in healthy individuals

Graft-versus-MDS effect after unrelated cord blood transplantation: a retrospective analysis of 752 patients registered at the Japanese Data Center for Hematopoietic Cell Transplantation

Expanding the repertoire of miRNAs and miRNA-offset RNAs expressed in multiple myeloma by small RNA deep sequencing

Antibody–drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study

Current status of autologous stem cell transplantation for multiple myeloma

Humanized anti-CD123 antibody facilitates NK cell antibody-dependent cell-mediated cytotoxicity (ADCC) of Hodgkin lymphoma targets via ARF6/PLD-1

Elevated IgM and abnormal free light chain ratio are increased in relatives from high-risk chronic lymphocytic leukemia pedigrees

Leukemic transformation among 1306 patients with primary myelofibrosis: risk factors and development of a predictive model

Deciphering the chronology of copy number alterations in Multiple Myeloma

Integrating precision medicine through evaluation of cell of origin in treatment planning for diffuse large B-cell lymphoma

Mice with Calr mutations homologous to human CALR mutations only exhibit mild thrombocytosis

Predicting long-term disease control in transplant-ineligible patients with multiple myeloma: impact of an MGUS-like signature

The role of cement augmentation with percutaneous vertebroplasty and balloon kyphoplasty for the treatment of vertebral compression fractures in multiple myeloma: a consensus statement from the International Myeloma Working Group (IMWG)

Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells

Multicenter validation of the flow measurement of classical monocyte fraction for chronic myelomonocytic leukemia diagnosis

The biological significance of histone modifiers in multiple myeloma: clinical applications

Deferred autologous stem cell transplantation in systemic AL amyloidosis

Prefibrotic myelofibrosis: treatment algorithm 2018

Ropeginterferon alpha-2b targets JAK2V617F-positive polycythemia vera cells in vitro and in vivo

Prognostic and therapeutic significance of phosphorylated STAT3 and protein tyrosine phosphatase-6 in peripheral-T cell lymphoma

GATA2 zinc finger 1 mutations are associated with distinct clinico-biological features and outcomes different from GATA2 zinc finger 2 mutations in adult acute myeloid leukemia

Low-level expression of SAMHD1 in acute myeloid leukemia (AML) blasts correlates with improved outcome upon consolidation chemotherapy with high-dose cytarabine-based regimens

Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma — an IMWG Research Project

Hydroxyurea prevents arterial and late venous thrombotic recurrences in patients with myeloproliferative neoplasms but fails in the splanchnic venous district. Pooled analysis of 1500 cases

Lenalidomide and dexamethasone in patients with relapsed multiple myeloma and impaired renal function: PrE1003, a PrECOG study

Recommendations for acquisition, interpretation and reporting of whole body low dose CT in patients with multiple myeloma and other plasma cell disorders: a report of the IMWG Bone Working Group

Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting

Lenalidomide plus R-CHOP21 in newly diagnosed diffuse large B-cell lymphoma (DLBCL): long-term follow-up results from a combined analysis from two phase 2 trials

Exosomes play a role in multiple myeloma bone disease and tumor development by targeting osteoclasts and osteoblasts

CD26 is a potential therapeutic target by humanized monoclonal antibody for the treatment of multiple myeloma

©2008-2020 OALib, Inc | Public user content licensed CC-BY 4.0 unless otherwise specified. OALib ISSN Online: 2333-9721 OALib ISSN Print: 2333-9705